Evidence map›Paper›PMID 24667150›Full record

ArticlePLoS medicine2014

Representation and misrepresentation of scientific evidence in contemporary tobacco regulation: a review of tobacco industry submissions to the UK Government consultation on standardised packaging.

Selda Ulucanlar, Gary J Fooks, Jenny L Hatchard, Anna B Gilmore

Abstract read
In one paragraph

Article in PLoS medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Perceptions of Illicit Tobacco Sources Following a Proposed Reduction in Tobacco Availability: A Qualitative Analysis of New Zealanders Who Smoke.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2023
    Article
  16. Article
  17. Corporate Political Activity: Taxonomies and Model of Corporate Influence on Public Policy.International journal of health policy and management · 2023
    Article
  18. Article
  19. Article
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Selda UlucanlarUniversity of Bath, Bath, United Kingdom; UK Centre for Alcohol and Tobacco Studies (UKCTAS), University of Bath, Bath, United Kingdom.
Gary J FooksUniversity of Bath, Bath, United Kingdom; UK Centre for Alcohol and Tobacco Studies (UKCTAS), University of Bath, Bath, United Kingdom.
Jenny L HatchardUniversity of Bath, Bath, United Kingdom; UK Centre for Alcohol and Tobacco Studies (UKCTAS), University of Bath, Bath, United Kingdom.
Anna B GilmoreUniversity of Bath, Bath, United Kingdom; UK Centre for Alcohol and Tobacco Studies (UKCTAS), University of Bath, Bath, United Kingdom.

Funding

Tobacco Companies, Global Governance and Public HealthR01CA160695 · NCI · UNIVERSITY OF BATH · PI GILMORE, ANNA B · 2011 to 2013
$1.3M
Cancer Research UK C38058/A15664Medical Research Council MR/K023195/1NCI NIH HHS R01 CA160695NCI NIH HHS R01CA160695
6 · The paper itself

Abstract

backgroundStandardised packaging (SP) of tobacco products is an innovative tobacco control measure opposed by transnational tobacco companies (TTCs) whose responses to the UK government's public consultation on SP argued that evidence was inadequate to support implementing the measure. The government's initial decision, announced 11 months after the consultation closed, was to wait for 'more evidence', but four months later a second 'independent review' was launched. In view of the centrality of evidence to debates over SP and TTCs' history of denying harms and manufacturing uncertainty about scientific evidence, we analysed their submissions to examine how they used evidence to oppose SP. METHODS AND

findingsWe purposively selected and analysed two TTC submissions using a verification-oriented cross-documentary method to ascertain how published studies were used and interpretive analysis with a constructivist grounded theory approach to examine the conceptual significance of TTC critiques. The companies' overall argument was that the SP evidence base was seriously flawed and did not warrant the introduction of SP. However, this argument was underpinned by three complementary techniques that misrepresented the evidence base. First, published studies were repeatedly misquoted, distorting the main messages. Second, 'mimicked scientific critique' was used to undermine evidence; this form of critique insisted on methodological perfection, rejected methodological pluralism, adopted a litigation (not scientific) model, and was not rigorous. Third, TTCs engaged in 'evidential landscaping', promoting a parallel evidence base to deflect attention from SP and excluding company-held evidence relevant to SP. The study's sample was limited to sub-sections of two out of four submissions, but leaked industry documents suggest at least one other company used a similar approach.

conclusionsThe TTCs' claim that SP will not lead to public health benefits is largely without foundation. The tools of Better Regulation, particularly stakeholder consultation, provide an opportunity for highly resourced corporations to slow, weaken, or prevent public health policies.

Indexed as

Government RegulationHealth PolicyProduct PackagingTobacco IndustryTobacco ProductsUnited Kingdom

Identifiers

PMID24667150
PMCPMC3965396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.